Acetohexamide
Dymelor (acetohexamide) is a small molecule pharmaceutical. Acetohexamide was first approved as Dymelor on 1982-01-01. It is used to treat type 2 diabetes mellitus in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetohexamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DYMELOR | Eli Lilly | N-013378 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 3 | 16 | 1 | 7 | 29 |
| Essential hypertension | D000075222 | I10 | — | 2 | 9 | 1 | — | 11 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 3 | 2 | — | 5 |
| Stable angina | D060050 | I20.8 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | 1 | — | — | 4 | ||
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ACETOHEXAMIDE |
| INN | acetohexamide |
| Description | Acetohexamide is an N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group. It has a role as a hypoglycemic agent and an insulin secretagogue. It is a N-sulfonylurea and a member of acetophenones. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 968-81-0 |
| RxCUI | 173 |
| ChEMBL ID | CHEMBL1589 |
| ChEBI ID | 28052 |
| PubChem CID | 1989 |
| DrugBank | DB00414 |
| UNII ID | QGC8W08I6I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 347 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,528 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more